mAbxience and Sandoz are targeting a $5.7 billion market with a proposed emicizumab biosimilar for hemophilia A.
|Articles|October 1, 2017
- BioPharm International-10-01-2017
- Volume 30
- Issue 10
BioPharm International, October 2017 Issue (PDF)
Click the title above to open the BioPharm International October 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 9 years ago
Improved Materials Enhance Parenteral Packagingalmost 9 years ago
Pharma’s Role in Puerto Rico’s Futurealmost 9 years ago
Control Viral Contaminants with Effective Testingalmost 9 years ago
Formulation of Biologics for Non-Invasive Deliveryalmost 9 years ago
FDA User Fees Promote Manufacturing Readinessalmost 9 years ago
Up and Away, M&Aalmost 9 years ago
Making Decisions Based on Riskalmost 9 years ago
The Challenges of PAT in the Scale-Up of Biologics Productionalmost 9 years ago
Optimizing Protein Aggregate Analysis by SECalmost 9 years ago
Development of Purification for Challenging Fc-Fusion ProteinsAdvertisement
Related to this article
Fayuvi scored 23.5 points higher than untreated peers on cognitive testing, backing the first-ever approval for a Sanfilippo syndrome A gene therapy.
Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
FDA compliance officers detailed 2026 guidance updates, online drug sale enforcement, and a first-of-its-kind AI-related warning letter at the PDA/FDA Joint Regulatory Conference.
Sanofi’s Jack Prior discusses how biopharmaceutical manufacturers can assess whether process data is ready for human and AI use, and the role of data quality, accessibility, governance, and AI in manufacturing.
Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.
Dualitas will screen over 300,000 bispecific combinations for Roche, backing a deal worth up to $1 billion in immunology research.
FDA's Francis R.W. Godwin (CDER) and Kathleen Jones, PhD (CBER) detail a record pace of drug warning letters and the CGMP deficiencies most commonly cited in biologics facility inspections.
Advertisement
Advertisement